
May 8 (Reuters) - Neurocrine Biosciences Inc NBIX.O:
NEUROCRINE BIOSCIENCES ANNOUNCES NEW RESULTS FROM EXPLORATORY ANALYSES OF THE PHASE 3 CAHTALYST™ PEDIATRIC STUDY DEMONSTRATING CRENESSITY™ REDUCES GLUCOCORTICOID DOSING WHILE MAINTAINING OR IMPROVING ANDROSTENEDIONE ACROSS PATIENT SUBGROUPS
NEUROCRINE BIOSCIENCES INC - CRENESSITY REDUCES GLUCOCORTICOID DOSING WHILE MAINTAINING ANDROSTENEDIONE LEVELS
NEUROCRINE BIOSCIENCES INC - DATA CONSISTENT ACROSS ALL PATIENT SUBGROUPS IN CAHTALYST STUDY
NEUROCRINE BIOSCIENCES INC - CRENESSITY GENERALLY WELL TOLERATED IN CAHTALYST STUDY